Scancell Holdings PLC Investor Webinar Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Julie Simmonds - Panmure Liberum Capital Ltd - Analyst : Thank you very much. Great data there. Excellent. I was just wondering in your discussions with potential partners, have there been any particular pushbacks that you've got? Because you talked about the positives. I was just wondering if there are any negatives that they had.

Question: Julie Simmonds - Panmure Liberum Capital Ltd - Analyst : Brilliant, thank you. And then, on the manufacturing process, you've obviously sorted -- you've got that in process. Is there going to be -- do you still need to actually manufacture the product for the clinical trial? Or is that now done and you're sort of waiting for the trial to start? LSEG STREETEVENTS | www.lseg.com | Contact Us consent of LSEG. 'LSEG' and the LSEG logo are registered trademarks of LSEG and its affiliated companies. DECEMBER 11, 2025 / 2:00PM, SCLP.L - Scancell Holdings PLC Investor Webinar and then on the manufacturing process, you've obviously sorted you've got that in process is there going to be, do you still need to actually manufacture the product for the clinical trial or is that now done and you're sort of waiting for the trial to start?

Question: Julie Simmonds - Panmure Liberum Capital Ltd - Analyst : Brilliant, thank you.

Question: Michael Mitchell - Cavendish - Analyst : Many thanks. Hi, there. Great presentation and thanks for taking my questions. Just looking forward to the Phase 3. You mentioned FDA alignment on PFS as primary endpoint. And I know you're still finalizing the design, but I just wondered what overall survival follow-up is expected? And also just to confirm that you do expect a single pivotal study is going to be sufficient? Thanks.

Question: Michael Mitchell - Cavendish - Analyst : That's great, thank you.

Question: Edward Sham - Singer Capital Markets Securities Ltd - Analyst : Thank you. Just two questions from me. So just the first one, so the data looks really exciting, but it's obviously quite technical, and there are a few moving parts to get our heads around, namely the ORR. So I was just wondering, can you give us your view on whether you feel more or less positive now following the updated readout? And then my second question was just around the discontinuation of the intradermal cohort. Has that partnership with the NHS Cancer Vaccine Launch Pad now ended then?

Question: Edward Sham - Singer Capital Markets Securities Ltd - Analyst : That's all really helpful. Thank you very much.

Question: Edward Brounger - Edison Group - Analyst : Hi, there, I'm calling on behalf of Jyoti Prakash, our healthcare analyst. I only have one small question, as most of my questions have been answered. But the data looks very encouraging, specifically, the target HLA population in Cohort 3. We were wondering if you're able to share the combined all-comers data for Cohort 3, as reference for comparison with Checkmate 067?

Question: Edward Brounger - Edison Group - Analyst : Great, thank you.